



## Aclaris Therapeutics to Present at Upcoming Investor Conferences

September 1, 2020

WAYNE, Pa., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in the following upcoming virtual investor conferences:

- **H.C. Wainwright & Co. 22nd Annual Global Investment Conference.** On Tuesday, September 15, 2020 at 12:30 p.m. ET, Dr. Neal Walker, the President and CEO of Aclaris, will present a company overview. Management will be available September 15th throughout the day for virtual one-on-one meetings with investors who are registered to attend the conference.
- **Cantor Virtual Global Healthcare Conference.** On Thursday, September 17, 2020 at 10:40 a.m. ET., Dr. Walker will participate in a fireside chat. Management will be available September 17th throughout the day for virtual one-on-one meetings with investors who are registered to attend the conference.

A live audio webcast of each presentation may be accessed through the Events page under the Investors section of Aclaris' website, [www.aclaristx.com](http://www.aclaristx.com). An archived version of each webcast will be available for 30 days.

### About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit [www.aclaristx.com](http://www.aclaristx.com).

### Aclaris Contact

[investors@aclariastx.com](mailto:investors@aclariastx.com)



Source: Aclaris Therapeutics, Inc.